For Investors
Partner with FluoLink
FluoLink is actively engaging with investors for our next phase of growth, clinical expansion and regulatory approval.
Protected IP
Granted method and device patents in key markets, supported by proprietary algorithms and calibration know-how.
Regulatory path
FluoRa 3.0 in preparation for CE marking, with the FDA pathway identified.
Clinical traction
More than 280 clinical measurements across deep brain stimulation, biopsy and resection procedures.
Health economics
One-insertion biopsy reduces trajectories and theatre time, with a measurable cost benefit per procedure.
Financial support
Research
Swedish Foundation for Strategic Research (SSF-MedX), Vinnova/Swelife, ALF, Region Östergötland and the Faculty of Science and Engineering at Linköping University.
Technology transfer
SSF-MedX, LiU Holding, Linköpings Affärsänglar, LKPG Invest AB and Vinnova/Swelife.
Supported by
Investment enquiries
